Clinical Trial Update: Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 double-blind, randomized, placebo-controlled trial of BIRT 2584 XX in patients with moderate-to-severe psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BIRT 2584 XX

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 2 | Status: COMPLETED